TMCnet News
Cara Therapeutics to Present Data at Kidney Week 2017STAMFORD, Conn., Oct. 16, 2017 (GLOBE NEWSWIRE) -- Cara Therapeutics, Inc. (Nasdaq:CARA), a biotechnology company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors, today announced upcoming CR845 presentations at Kidney Week 2017, the American Society of Nephrology's Annual Meeting, to be held October 31 – November 5, 2017 in New Orleans, LA. Presentations will include clinical data from a recently completed Phase 2b trial of I.V. CR845 in hemodialysis patients suffering from moderate-to-severe pruritus. Details for the presentations are as follows: CR845 Oral Presentation:
CR845 Poster Presentation:
About Cara Therapeutics Cara Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing new chemical entities designed to alleviate pain and pruritus by selectively targeting peripheral kappa opioid receptors (KORs). Cara is developing a novel and proprietary class of product candidates, led by CR845, a first-in-class KOR agonist that targets the body's peripheral nervous system. In Phase 2 trials, CR845 has demonstrated statistically significant reductions in itch intensity and concomitant improvement in quality of life measures in patients with moderate-to-severe chronic kidney disease-associated pruritus. Additionally, CR845 has demonstrated initial signs of efficacy in patients with moderate-to-severe pain, without inducing many of the undesirable side effects typically associated with currently available opioid pain therapeutics. INVESTOR CONTACT: MEDIA CONTACT: |